SCHEMBL24528893

SCHEMBL24528893

CCOC(=O)CCc1ccc2c(c1)C(C)N(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.44
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NR1H2 P55055 1/20 0.39
KMT2A Q03164 1/20 0.39
CASR P41180 1/20 0.37
ESR2 Q92731 1/20 0.37
GHSR Q92847 1/20 0.37
NOTUM Q6P988 1/20 0.36
CHRM5 P08912 2/20 0.36
HTR1A P08908 1/20 0.36
SLC6A2 P23975 1/20 0.36
HRH2 P25021 1/20 0.36
ADRA1D P25100 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24529088 0.93 HRH3 (0.41) HRH3CYP4F2CYP4A11KDM4EALDH1A1
SCHEMBL30828033 0.93 HRH3 (0.41) HRH3CYP4F2CYP4A11KDM4EALDH1A1
SCHEMBL24528888 0.89 NR1H2 (0.44) HRH3NR1H2KMT2AESR2GHSR
SCHEMBL29088771 0.86 HRH3 (0.47) HRH3CYP4F2CYP4A11KMT2ANOTUM
SCHEMBL24528889 0.85 KMT2A (0.39) NR1H2KMT2AESR2GHSRLMNA
SCHEMBL5776482 0.84 NR1H2 (0.44) NR1H2KMT2AESR2GHSRLMNA
SCHEMBL24528894 0.83 NR1H2 (0.40) NR1H2KMT2AESR2GHSRLMNA
SCHEMBL22494235 0.83 ESR2 (0.50) HRH3CYP4F2CYP4A11KDM4EALDH1A1
SCHEMBL19643138 0.82 GHSR (0.42) HRH3KMT2AGHSRLMNAMAPK1
SCHEMBL31680225 0.82 GHSR (0.42) HRH3KMT2AGHSRLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240115711-A1 Novel Bifunctional Molecules For Targeted Protein Degradation AMPHISTA THERAPEUTICS LIMITED (GB) 2024-04-11 US disclosed
EP-4263511-A1 NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION Amphista Therapeutics Ltd (GB) 2023-10-25 EP disclosed
CN-116897150-A Novel bifunctional molecules for protein-targeted degradation 安菲斯塔治疗有限公司 2023-10-17 CN disclosed
WO-2022129925-A1 NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2022-06-23 WO disclosed
WO-2022129925-A1 NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240115711-A1 Novel Bifunctional Molecules For Targeted Protein Degradation PSMG3, MYCBP2, PSME2 HRH3 4098/4885CYP4F2 4248/4885CYP4A11 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.